Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Novel AR-targeted therapies in prostate cancer: CYP11A1 inhibitors, AR degraders and RIPTACs

Robert Jones • 25 Oct 2026
ESMO 2026
Genitourinary Cancer Prostate Cancer JNJ-6143 Opevesostat

Robert Jones, MD, PhD, University of Glasgow, Glasgow, UK, discusses novel androgen receptor (AR)-targeted therapies for advanced prostate cancer, including steroid hormone biosynthesis inhibitors like opevesostat, AR degraders, and regulated induced proximity targeting chimeras (RIPTACs), a new class of drugs which bind to the AR and BRD4 to induce cell killing. Dr Jones highlights the potential of these therapies to overcome resistance to current AR-targeted treatments and notes that early data for the RIPTAC JNJ-6143 shows high response rates and good tolerability. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Robert Jones

ESMO 2026 updates in MIBC: TROPHY-U-01, KEYNOTE-866 and ENERGIZE
5:54
ESMO 2026 updates in MIBC: TROPHY-U-01, KEYNOTE-866 and ENERGIZE
Robert Jones • 25 Oct 2026
Areas of unmet need in metastatic urothelial carcinoma
2:04
Areas of unmet need in metastatic urothelial carcinoma
Robert Jones • 4 Jun 2022
ASCO 2022: genitourinary cancer highlights
1:10
ASCO 2022: genitourinary cancer highlights
Robert Jones • 4 Jun 2022
Replacing the current standard of care for urothelial carcinoma
0:58
Replacing the current standard of care for urothelial carcinoma
Robert Jones • 4 Jun 2022

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals